BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36181911)

  • 1. Functional connectivity differences in the amygdala are related to the antidepressant efficacy of ketamine in patients with anxious depression.
    Yuan S; Luo X; Chen X; Wang M; Hu Y; Zhou Y; Ning Y; Zhang B
    J Affect Disord; 2023 Jan; 320():29-36. PubMed ID: 36181911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional connectivity of the amygdala subregions and the antidepressant effects of repeated ketamine infusions in major depressive disorder.
    Liu H; Wang C; Lan X; Li W; Zhang F; Hu Z; Ye Y; Ning Y; Zhou Y
    Eur Psychiatry; 2024 Apr; 67(1):e33. PubMed ID: 38572583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression.
    Siegel JS; Palanca BJA; Ances BM; Kharasch ED; Schweiger JA; Yingling MD; Snyder AZ; Nicol GE; Lenze EJ; Farber NB
    Psychopharmacology (Berl); 2021 Apr; 238(4):1157-1169. PubMed ID: 33483802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain functional abnormalities in the amygdala subregions is associated with anxious depression.
    Qiao J; Tao S; Wang X; Shi J; Chen Y; Tian S; Yao Z; Lu Q
    J Affect Disord; 2020 Nov; 276():653-659. PubMed ID: 32871697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.
    Ionescu DF; Luckenbaugh DA; Niciu MJ; Richards EM; Slonena EE; Vande Voort JL; Brutsche NE; Zarate CA
    J Clin Psychiatry; 2014 Sep; 75(9):e932-8. PubMed ID: 25295436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional connectivity between the amygdala and subgenual cingulate gyrus predicts the antidepressant effects of ketamine in patients with treatment-resistant depression.
    Nakamura T; Tomita M; Horikawa N; Ishibashi M; Uematsu K; Hiraki T; Abe T; Uchimura N
    Neuropsychopharmacol Rep; 2021 Jun; 41(2):168-178. PubMed ID: 33615749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeated intravenous infusions of ketamine: Neurocognition in patients with anxious and nonanxious treatment-resistant depression.
    Liu W; Zhou Y; Zheng W; Wang C; Zhan Y; Lan X; Zhang B; Li H; Chen L; Ning Y
    J Affect Disord; 2019 Dec; 259():1-6. PubMed ID: 31430662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ketamine-induced hippocampal functional connectivity alterations associated with clinical remission in major depression.
    Zhang F; Wang C; Lan X; Li W; Ye Y; Liu H; Hu Z; You Z; Zhou Y; Ning Y
    J Affect Disord; 2023 Mar; 325():534-541. PubMed ID: 36646174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antidepressant and antisuicidal effects of ketamine on the functional connectivity of prefrontal cortex-related circuits in treatment-resistant depression: A double-blind, placebo-controlled, randomized, longitudinal resting fMRI study.
    Chen MH; Lin WC; Tu PC; Li CT; Bai YM; Tsai SJ; Su TP
    J Affect Disord; 2019 Dec; 259():15-20. PubMed ID: 31437695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder.
    Aust S; Gärtner M; Basso L; Otte C; Wingenfeld K; Chae WR; Heuser-Collier I; Regen F; Cosma NC; van Hall F; Grimm S; Bajbouj M
    Eur Neuropsychopharmacol; 2019 Apr; 29(4):529-538. PubMed ID: 30772118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of low-dose ketamine infusion in anxious vs nonanxious depression: revisiting the Adjunctive Ketamine Study of Taiwanese Patients with Treatment-Resistant Depression.
    Chen MH; Lin WC; Wu HJ; Bai YM; Li CT; Tsai SJ; Hong CJ; Tu PC; Cheng CM; Su TP
    CNS Spectr; 2021 Aug; 26(4):362-367. PubMed ID: 32419678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Habenula Connectivity and Intravenous Ketamine in Treatment-Resistant Depression.
    Rivas-Grajales AM; Salas R; Robinson ME; Qi K; Murrough JW; Mathew SJ
    Int J Neuropsychopharmacol; 2021 May; 24(5):383-391. PubMed ID: 33249434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The functional connectivity of the middle frontal cortex predicts ketamine's outcome in major depressive disorder.
    Zhang F; Wang C; Lan X; Li W; Fu L; Ye Y; Liu H; Wu K; Zhou Y; Ning Y
    Front Neurosci; 2022; 16():956056. PubMed ID: 36188452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
    Murrough JW; Perez AM; Pillemer S; Stern J; Parides MK; aan het Rot M; Collins KA; Mathew SJ; Charney DS; Iosifescu DV
    Biol Psychiatry; 2013 Aug; 74(4):250-6. PubMed ID: 22840761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of Excellence.
    Lipsitz O; McIntyre RS; Rodrigues NB; Kaster TS; Cha DS; Brietzke E; Gill H; Nasri F; Lin K; Subramaniapillai M; Kratiuk K; Teopiz K; Lui LMW; Lee Y; Ho R; Shekotikhina M; Mansur RB; Rosenblat JD
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Mar; 105():110126. PubMed ID: 33031861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antianhedonic effects of serial intravenous subanaesthetic ketamine in anxious versus nonanxious depression.
    Zheng W; Yang XH; Gu LM; Tan JQ; Zhou YL; Wang CY; Ning YP
    J Affect Disord; 2022 Sep; 313():72-76. PubMed ID: 35772627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.
    Dwyer JB; Landeros-Weisenberger A; Johnson JA; Londono Tobon A; Flores JM; Nasir M; Couloures K; Sanacora G; Bloch MH
    Am J Psychiatry; 2021 Apr; 178(4):352-362. PubMed ID: 33653121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression.
    Zhou Y; Zheng W; Liu W; Wang C; Zhan Y; Li H; Chen L; Li M; Ning Y
    J Psychopharmacol; 2018 Oct; 32(10):1118-1126. PubMed ID: 30260273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: A randomized controlled study.
    Li CT; Chen MH; Lin WC; Hong CJ; Yang BH; Liu RS; Tu PC; Su TP
    Hum Brain Mapp; 2016 Mar; 37(3):1080-90. PubMed ID: 26821769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuation phase intravenous ketamine in adults with treatment-resistant depression.
    Vande Voort JL; Morgan RJ; Kung S; Rasmussen KG; Rico J; Palmer BA; Schak KM; Tye SJ; Ritter MJ; Frye MA; Bobo WV
    J Affect Disord; 2016 Dec; 206():300-304. PubMed ID: 27656788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.